WEBULL
WebtradeDownload

Following The Recall, Is CONMED (CNMD) Now Fully Valued?

Simply Wall St · 2d ago

CONMED (CNMD) has moved into focus after a voluntary Class II recall of its Genesys CrossFT Suture Anchor, which is tied to incorrect patient implant cards that affect device identification and traceability.

Recent trading in CONMED reflects that tension between product risk and recovery hopes. The share price has eased over the past week and month, yet the 90-day share price return of 36.38% and year-to-date gain of 15.82% signal improving momentum compared with a much weaker 1-year total shareholder return, which declined 10.8%, and longer-term total shareholder returns that are down over 50%.

Compare how CONMED stacks up against other medical and healthcare device players by scanning the hand picked list of solid balance sheet and fundamentals (24 results) in seconds.

After a sharp 90 day rebound and years of weak total returns, CONMED now sits at a crossroads. Is the real upside still ahead, or has most of the rerating already played out in the current price?

Most Popular Narrative: 3.1% Overvalued

Against CONMED's last close of $46.93, the most widely followed narrative pins fair value at $45.50, a small discount that still suggests investors are already pricing in a fair amount of optimism.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is poised to support durable procedure volume growth and increase recurring revenue, driving sustained top-line growth.

Read the complete narrative. Read the complete narrative.

Want to understand why this story supports a higher long term earnings profile for CONMED? The narrative focuses on compounding profit growth, firmer margins and a future earnings multiple that looks very different from today. The full case explains how those elements fit together into that $45.50 fair value.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, supply chain setbacks in orthopedics and heavy reliance on hospital capital budgets could easily derail the CONMED narrative if those pressures persist or intensify.

Find out about the key risks to this CONMED narrative.

Another View: CONMED on Earnings Multiples

That 3.1% premium to the $45.50 fair value is one story for CONMED. A different lens looks at the current P/E of 24.9x versus a fair ratio of 31.9x and an industry average of 26.3x. The gap hints at possible upside, but also raises the question of whether the market is discounting CONMED's risks for a reason.

For a closer look at how this earnings-based view fits into the wider picture, including peers, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

NYSE:CNMD P/E Ratio as at Sep 2026
NYSE:CNMD P/E Ratio as at Sep 2026

Next Steps

Balanced or lopsided, the mix of optimism and concern around CONMED is only useful if you stress test it yourself right now. Run through the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond CONMED?

If you stop with CONMED, you only see one angle. Use the Simply Wall Street Screener to surface fresh opportunities that might suit your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.